Live Breaking News & Updates on Oneness biotech co ltd

Stay informed with the latest breaking news from Oneness biotech co ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Oneness biotech co ltd and stay connected to the pulse of your community

Health Ministry approves the first natural products with therapeutic claims, says Health DG

PETALING JAYA: The Health Ministry has approved the first registration of natural products with therapeutic claims, says Datuk Dr Muhammad Radzi Abu Hassan.

Nanchou , Tainan-municipality , Taiwan , Petaling , Malaysia-general- , Malaysia , Malaysian , Muhammad-radzi , Muhammad-radzi-abu-hassan , National-pharmaceutical-regulatory-division , Health-ministry , Drug-control-authority-meeting

16 Taiwanese firms included in 2023 Bloomberg Gender-Equality Index

Taipei, Feb. 1 (CNA) Ten more companies headquartered in Taiwan were included in the 2023 Bloomberg Gender Equality Index (GEI) Tuesday, bringing the number of Taiwanese firms on the list to 16, the biggest increase of any country in the Asia-Pacific region, according to a local market advisor.

Taipei , T-ai-pei , Taiwan , Zhen-ding , Yunlin-xian , Taiwanese , Jeffrey-wu , Alex-lee , Shih-hsiu-chuan , Taiwan-cooperative-financial-holding-co , Semiconductors-corp , King-town-bank-co-ltd

Oneness Biotech Co., Ltd.'s FESPIXON Honored at the International Innovation Awards 2022

SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place in Bangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, industry leaders, and policymakers worldwide. As one of the pillars of the Innovation Revolution movement spearheaded by Enterprise Asia since 2017, the awards aim to create an innovation ecosystem for enterprises which is held annually to recognize outstanding innovations across the globe. The awards drew an exceptional mix of submissions from various industries across 19 countries. 39 innovations were selected and crowned winners from over 200 applications through undergoing a rigorous evaluation process by a jury of prominent judges across three categories: Product, Service & Solution, and Organization & Culture. Oneness Biotech Co., Ltd.'s Award-Winning Innovation Oneness Biotech Co., Ltd. was awarded for its groundbreaking innovation, FESPIXON, under the Product Category. The novel macrophage-regulating drug was developed by the company as a breakthrough treatment for diabetic foot ulcers (DFUs). DFU is the main complication of diabetes mellitus that leads to a high disability rate of diabetes and can be life-threatening in severe cases. DFUs and subsequent amputation incur enormous health and economic burdens to patients, healthcare systems, and societies. Along with the increase in the diabetic population, the global prevalence of diabetic foot ulcers has been 6.3% among DM patients, which means more than 30 million patients are living with an ulcer. There was a lack of pharmacological therapeutic approaches successfully addressing DFUs in the past 20 years. FESPIXON is a medical breakthrough with proven scientific evidence in treating DFUs in clinical trials and the real world. Physicians have shared positive feedback on FESPIXON's outstanding limb-salving effect in Wagner Grade 3 and 4 ulcers and its extended use in multiple indications. It is believed that FESPIXON will be able to promote the healing of foot ulcers of those patients and thereby reduce amputation and prevent disability. About Enterprise Asia Enterprise Asia is a non-governmental organization in the pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development. Please visit www.enterpriseasia.orgfor more information. About International Innovation Awards The International Innovation Awards is an annual recognition program that recognizes outstanding innovations, and in the process, encourages organizations to continue investing in innovations. For more information, visitwww.innovationaward.org. About the International Innovation Summit The International Innovation Summit annually provides an unparalleled platform for innovators that is power packed with networking and sharing of insights with an elite community of business leaders. The summit aims to resolve major challenges in innovation structures and at the same tie search for opportunities and new ideas to drive business growth for the future. For more information, visitwww.innosummit.org.

Bangkok , Krung-thep-mahanakhon , Thailand , Singapore , Oneness-biotech-co-ltd , Service-solution , International-innovation-summit , International-innovation-awards , Organization-culture , International-innovation , Innovation-revolution

MSCI cuts weightings in two indices

Global index provider MSCI Inc yesterday cut Taiwan’s weighting in two indices, but raised the weighting in another after a semi-annual review, Taiwan Stock Exchange data showed.
MSCI lowered Taiwan’s weighting in the MSCI Emerging Markets Index, which is closely watched by foreign institutional investors, by 0.11 percentage points to 15.56 percent, the exchange said.
That revised weighting is still higher than a range of 11.46 percent to 14.21 percent over the past three years, it said.
MSCI also lowered Taiwan’s weighting in the MSCI All-Country Asia ex-Japan Index to 17.9 percent from 18.01 percent, while the company raised Taiwan’s weighting in the

China , Taipei , T-ai-pei , Taiwan , Japan , Taiwanese , Hiwin-technologie , Karen-chen , Powerchip-semiconductor-manufacturing-corp , Taiwan-stock-exchange , Airways-corp , China-airlines-ltd

Exceptionally Robust Asthma Pipeline with More Than 100+

Asthma is considered to be one of the world's most common diseases affecting the population, and is also a life-threatening condition affecting patients'...

Tianqing , Zhejiang , China , United-states , Suzhou , Jiangsu , Aslan-pharma , Aquilon-pharma , Chiesi-farmaceutici , Las-vegas , Synermore-biologics , Glaxosmithkline

Diabetic Foot Ulcer Treatment Market Expected to Witness a High Jump as the Market is Projected to Grow with a CAGR of 17.0% During the Study Period (2018-2030)

leading cause of non-traumatic lower extremity amputations in the United States, and approximately
14-24% of patients with diabetes who develop a foot ulcer will require an
amputation. Foot ulceration precedes
85% of diabetes-related amputations.
The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer.
Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and anti-infectives,
around 78% of the current market is captured by these two classes of drugs.
There is only one drug,
Regranex (Becaplermin), which the FDA has approved.
Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc) in December 1997.

Germany , Italy , Japan , United-states , United-kingdom , France , Spain , Shruti-thakur , Amniox-tissuetech , Donaperminogene-seltoplasmid , Regranex-becaplermin , Ticeba-gmb